Genmab AS 2023 AR2
The report outlines Genmab's financial and operational achievements for 2023, highlighting the successful launch of EPKINLY in the U.S. and Japan and the expansion of its antibody therapeutics pipeline. Genmab reached a milestone of 2,000 international team members and opened a new headquarters in Copenhagen. The company advanced its sustainability commitments by preparing for upcoming CSRD and SEC climate-related disclosure requirements. Additionally, Genmab mapped its full carbon footprint for the first time and established greenhouse gas emissions reduction targets for 2030.
Company: Genmab AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: AR2
Pages: 138
Genmab AS
Annual Report
The report outlines Genmab's financial and operational achievements for 2023, highlighting the successful launch of EPKINLY in the U.S. and Japan and the expansion of its antibody therapeutics pipeline. Genmab reached a milestone of 2,000 international team members and opened a new headquarters in Copenhagen. The company advanced its sustainability commitments by preparing for upcoming CSRD and SEC climate-related disclosure requirements. Additionally, Genmab mapped its full carbon footprint for the first time and established greenhouse gas emissions reduction targets for 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Women on Board
Women in Management
Employees